01—Abstract
Summary
Summary of the 8-K filed January 13, 2025. Cited figures are marked; the original filing is the authoritative source.
Regeneron's January 13, 2025 Form 8-K, furnished under Items 2.02 and 7.01, pairs preliminary (unaudited) fourth-quarter and full-year 2024 results with the company's J.P.
Morgan Healthcare Conference presentation. The headline numbers are about $6 billiona in aggregate U.S. net sales for EYLEA HD and EYLEA in 2024, up 1% year over year, and Libtayo surpassing $1 billion in 2024 annual net sales. The filing also discloses a fourth-quarter 2024 acquired IPR&D charge of approximately $14 million pre-tax, which reduces GAAP and non-GAAP diluted EPS by about $0.11.
Results are not finalized and remain subject to closing procedures. The pipeline and regulatory updates are the other focus. Libtayo delivered the first statistically significant disease-free survival benefit in high-risk adjuvant cutaneous squamous cell carcinoma (68%b risk reduction, HR 0.32), with an FDA submission planned for the first half of 2025.
The linvoseltamab BLA was resubmitted with launch expected in mid-2025, and the odronextamab FL BLA resubmission is planned for Q1 2025. Dupixent is now used by over one million patients globally, with a COPD launch underway and a CSU FDA decision due April 18, 2025.
Key investor considerations include the EYLEA HD pre-filled syringe launch (mid-2025), the April 20, 2025 PDUFA date for extended EYLEA HD dosing, and 2025 Phase 3 readouts for itepekimab in COPD and fianlimab plus Libtayo in melanoma. The filing also includes standard forward-looking statement cautions and notes that EYLEA HD and EYLEA results were partly boosted by about $85 millionc of wholesaler inventory build for EYLEA.
02—Key points
Key Highlights
- Preliminary 2024 aggregate U.S. net sales of EYLEA HD and EYLEA were about $6 billion, up 1% year over year, with Q4 2024 U.S. sales of $1.5 billion; Q4 was favorably affected by roughly $85 million of higher EYLEA wholesaler inventory.
- Libtayo exceeded $1 billion in 2024 annual net sales and showed a statistically significant adjuvant CSCC benefit (HR 0.32), a result where Keytruda failed; FDA submission is planned for 1H 2025.
- Q4 2024 acquired IPR&D charge of approximately $14 million pre-tax, reducing GAAP and non-GAAP diluted EPS by about $0.11; Regeneron does not forecast these charges.
- Dupixent is used by over one million patients globally, with the COPD launch underway and a CSU FDA decision due April 18, 2025 and a bullous pemphigoid sBLA submitted in Q4 2024.
- Linvoseltamab BLA resubmitted after resolution of third-party manufacturing issues, with launch anticipated mid-2025.
- EYLEA HD pre-filled syringe submission completed with launch expected by mid-2025; extended-dosing PDUFA date is April 20, 2025.
- Pipeline catalysts for 2025 include itepekimab Phase 3 COPD data (2H 2025), fianlimab plus Libtayo Phase 3 in 1L melanoma (2H 2025), and Factor XI antibodies advancing to Phase 3 trials.
03—Questions
Frequently Asked Questions
What is the financial impact of the Q4 2024 acquired IPR&D charge?
Regeneron expects an acquired IPR&D charge of approximately $14 million pre-tax in Q4 2024, primarily from asset acquisitions. It reduces both GAAP and non-GAAP diluted EPS by about $0.11. The company does not forecast these charges because their timing and size are uncertain.
How did EYLEA HD and EYLEA perform in 2024?
On a preliminary, unaudited basis, combined U.S. net product sales were about $6 billion for 2024, up 1% year over year, and remained the U.S. anti-VEGF category leader. Q4 2024 sales of $1.5 billion were boosted by roughly $85 million of higher EYLEA wholesaler inventory, partly offset by lower EYLEA HD inventory.
Are these 2024 results final?
No. The fourth-quarter and full-year 2024 figures are preliminary and unaudited, remain subject to financial statement closing procedures, and may differ from the final reported results.
What are the most important near-term regulatory catalysts?
Key dates include the Dupixent CSU FDA decision by April 18, 2025, the EYLEA HD extended-dosing PDUFA date of April 20, 2025, the linvoseltamab FDA decision expected around mid-2025, and the EYLEA HD pre-filled syringe launch expected by mid-2025.
What did the Libtayo adjuvant CSCC trial show?
In the Phase 3 trial, adjuvant Libtayo reduced the risk of disease recurrence or death by 68% versus placebo (HR 0.32; 95% CI 0.20-0.51; p<0.0001). Grade 3 or higher adverse events occurred in 24% of the Libtayo arm versus 14% of the placebo arm. The company plans an FDA submission in the first half of 2025.
04—Continue